Calidi Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Calidi Biotherapeutics (CLDI).

Price Target Range — 3 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$3200

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 27, 2024	Ladenburg Thalmann	Aydin Huseynov	Initiate	Buy	$1
May 15, 2024	Baird	Joel Beatty	PT Cut	Outperform	$5→$2
Mar 21, 2024	Baird	Joel Beatty	PT Cut	Outperform	$9→$5
Mar 21, 2024	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$11→$2
Nov 22, 2023	HC Wainwright & Co.	Robert Burns	Initiate	Buy	$11

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ladenburg Thalmann Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $1

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and announces Price Target of $1.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $2

Baird analyst Joel Beatty maintains Calidi Biotherapeutics (AMEX:CLDI) with a Outperform and lowers the price target from $4.5 to $2.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $4.5

Baird analyst Joel Beatty maintains Calidi Biotherapeutics (AMEX:CLDI) with a Outperform and lowers the price target from $9 to $4.5.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Calidi Biotherapeutics, Lowers Price Target to $2

HC Wainwright & Co. analyst Robert Burns maintains Calidi Biotherapeutics (AMEX:CLDI) with a Buy and lowers the price target from $11 to $2.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $11

HC Wainwright & Co. analyst Robert Burns initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc (NYSE: CLDI), which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment.

Vandana Singh

Calidi Biotherapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Calidi Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ladenburg Thalmann Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $1

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $2

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $4.5

PRO
HC Wainwright & Co. Maintains Buy on Calidi Biotherapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $11

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

People Also Watch

People Also Watch

Calidi Biotherapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Calidi Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLadenburg Thalmann Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $1

PROBaird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $2

PROBaird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $4.5

PROHC Wainwright & Co. Maintains Buy on Calidi Biotherapeutics, Lowers Price Target to $2

PROHC Wainwright & Co. Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $11

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

People Also Watch

People Also Watch

PRO
Ladenburg Thalmann Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $1

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $2

PRO
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $4.5

PRO
HC Wainwright & Co. Maintains Buy on Calidi Biotherapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $11